Leerink analyst Geoffrey Porges lowered his price target for Biogen to $319 from $328 on valuation following quarterly results, with the company reporting revenue 1% below consensus and EPS that beat consensus by 7.5%. The analyst reiterates a Market Perform rating on the shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here